REGN Earnings Regeneron Pharmaceuticals
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–60 of 60
| Q3 2026 | 2026-09-30 | 18.45 | 2026-10-30 | 10-Q |
| Q2 2026 | 2026-06-30 | 12.23 | 2026-07-30 | 10-Q |
| Q1 2026 | 2026-03-31 | 6.75 | 2026-04-29 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | 7.78 | 2026-02-04 | 10-K |
| FY 2025 | 2025-12-31 | 41.48 | 2026-02-04 | 10-K |
| Q3 2025 | 2025-09-30 | 13.62 | 2025-10-28 | 10-Q |
| Q2 2025 | 2025-06-30 | 12.81 | 2025-08-01 | 10-Q |
| Q1 2025 | 2025-03-31 | 7.27 | 2025-04-29 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | 8.12 | 2025-02-05 | 10-K |
| FY 2024 | 2024-12-31 | 38.34 | 2025-02-05 | 10-K |
| Q3 2024 | 2024-09-30 | 11.54 | 2024-10-31 | 10-Q |
| Q2 2024 | 2024-06-30 | 12.41 | 2024-08-01 | 10-Q |
| Q1 2024 | 2024-03-31 | 6.27 | 2024-05-02 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | 10.21 | 2024-02-05 | 10-K |
| FY 2023 | 2023-12-31 | 34.77 | 2024-02-05 | 10-K |
| Q3 2023 | 2023-09-30 | 8.89 | 2023-11-02 | 10-Q |
| Q2 2023 | 2023-06-30 | 8.50 | 2023-08-03 | 10-Q |
| Q1 2023 | 2023-03-31 | 7.17 | 2023-05-04 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | 10.48 | 2023-02-06 | 10-K |
| FY 2022 | 2022-12-31 | 38.22 | 2023-02-06 | 10-K |
| Q3 2022 | 2022-09-30 | 11.66 | 2022-11-03 | 10-Q |
| Q2 2022 | 2022-06-30 | 7.47 | 2022-08-03 | 10-Q |
| Q1 2022 | 2022-03-31 | 8.61 | 2022-05-04 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | 19.58 | 2022-02-07 | 10-K |
| FY 2021 | 2021-12-31 | 71.97 | 2022-02-07 | 10-K |
| Q3 2021 | 2021-09-30 | 14.33 | 2021-11-04 | 10-Q |
| Q2 2021 | 2021-06-30 | 27.97 | 2021-08-05 | 10-Q |
| Q1 2021 | 2021-03-31 | 10.09 | 2021-05-06 | 10-Q |
| Q4 2020 | 2020-12-31 | 10.24 | 2021-02-08 | 10-K |
| FY 2020 | 2020-12-31 | 30.52 | 2021-02-08 | 10-K |
| Q3 2020 | 2020-09-30 | 7.39 | 2020-11-05 | 10-Q |
| Q2 2020 | 2020-06-30 | 7.61 | 2020-08-05 | 10-Q |
| Q1 2020 | 2020-03-31 | 5.43 | 2020-05-05 | 10-Q |
| Q4 2019 | 2019-12-31 | 6.93 | 2020-02-07 | 10-K |
| FY 2019 | 2019-12-31 | 18.46 | 2020-02-07 | 10-K |
| Q3 2019 | 2019-09-30 | 5.86 | 2019-11-05 | 10-Q |
| Q2 2019 | 2019-06-30 | 1.68 | 2019-08-06 | 10-Q |
| Q1 2019 | 2019-03-31 | 3.99 | 2019-05-07 | 10-Q |
| Q4 2018 | 2018-12-31 | 7.15 | 2019-02-07 | 10-K |
| FY 2018 | 2018-12-31 | 21.29 | 2019-02-07 | 10-K |
| Q3 2018 | 2018-09-30 | 5.17 | 2018-11-06 | 10-Q |
| Q2 2018 | 2018-06-30 | 4.82 | 2018-08-02 | 10-Q |
| Q1 2018 | 2018-03-31 | 4.16 | 2018-05-03 | 10-Q |
| Q4 2017 | 2017-12-31 | 1.50 | 2018-02-08 | 10-K |
| FY 2017 | 2017-12-31 | 10.34 | 2018-02-08 | 10-K |
| Q3 2017 | 2017-09-30 | 3.32 | 2017-11-08 | 10-Q |
| Q2 2017 | 2017-06-30 | 3.34 | 2017-08-03 | 10-Q |
| Q1 2017 | 2017-03-31 | 2.16 | 2017-05-04 | 10-Q |
| Q4 2016 | 2016-12-31 | 2.19 | 2017-02-09 | 10-K |
| FY 2016 | 2016-12-31 | 7.70 | 2017-02-09 | 10-K |
| Q3 2016 | 2016-09-30 | 2.27 | 2016-11-04 | 10-Q |
| Q2 2016 | 2016-06-30 | 1.69 | 2016-08-04 | 10-Q |
| Q1 2016 | 2016-03-31 | 1.59 | 2016-05-05 | 10-Q |
| Q4 2015 | 2015-12-31 | 1.34 | 2016-02-11 | 10-K |
| FY 2015 | 2015-12-31 | 5.52 | 2016-02-11 | 10-K |
| Q3 2015 | 2015-09-30 | 1.82 | 2015-11-04 | 10-Q |
| Q2 2015 | 2015-06-30 | 1.69 | 2015-08-04 | 10-Q |
| Q1 2015 | 2015-03-31 | 0.66 | 2015-05-07 | 10-Q |
| Q4 2014 | 2014-12-31 | 0.78 | 2015-02-12 | 10-K |
| FY 2014 | 2014-12-31 | 2.98 | 2015-02-12 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.